



D.A. Montisano<sup>1</sup>, A. Parisi<sup>1</sup>, A. Raggi<sup>2</sup>, L. Grazzi<sup>1</sup>

<sup>1</sup> Headache Center, Neuroalgology dpt - Neurological Institute Carlo Besta IRCCS Foundation, Milan, Italy;

<sup>2</sup> Neurology, Public Health and Disability Unit - Neurological Institute Carlo Besta IRCCS Foundation, Milan, Italy;

## OBJECTIVE

The aim was to assess therapeutic adherence and tolerability of Atogepant 60mg in migraine patients.

## METHODS



### Online Survey:

- Side effect and weight lost;
- Adherence;
- Efficacy despite some "misses";
- Acute efficacy;

## CONCLUSIONS


Atogepant proved to be a well-tolerated treatment, with high adherence in actual clinical practice.

More than 60% of patients reported a 2h pain-free when taking pills concomitantly with a migraine attack.

Adverse effects were negligible; some patients also reported weight loss.


## RESULTS

| Populations      |          |
|------------------|----------|
| Age              | 31±8     |
| Sex              | 28F – 7M |
| Treatment period | 24 weeks |




**1,5Kg lost\***  
 (\*patients not on diet)


Missed Pills (for month)



Changes in health status if a dose was missed



2h Pain Free in acute setting



Discontinued for AE at 6 months FU

